NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $6.09 +0.13 (+2.18%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abeona Therapeutics Stock (NASDAQ:ABEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$6.01▼$6.1450-Day Range$5.56▼$7.4652-Week Range$4.00▼$7.65Volume889,559 shsAverage Volume1.65 million shsMarket Capitalization$348.23 millionP/E RatioN/ADividend YieldN/APrice Target$19.33Consensus RatingHold Company Overview Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need. The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting. Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.AI Generated. May Contain Errors. Read More Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 539th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingAbeona Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAbeona Therapeutics has a consensus price target of $19.33, representing about 217.5% upside from its current price of $6.09.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.92) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.76% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 12.89, which indicates bearish sentiment.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 3.07%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.12 News SentimentAbeona Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.Search Interest6 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,709,923.00 in company stock.Percentage Held by Insiders7.10% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABEO Stock News HeadlinesEquities Analysts Set Expectations for ABEO FY2026 EarningsAugust 22 at 2:13 AM | americanbankingnews.comAbeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement MilestoneAugust 21 at 7:11 PM | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Abeona (ABEO) Q2 2026 Earnings Call TranscriptAugust 20 at 2:28 PM | finance.yahoo.comABEO: Zevaskyn® Launch Gains MomentumAugust 17, 2026 | finance.yahoo.comAbeona Therapeutics Inc. Q2 2026 Earnings Call SummaryAugust 14, 2026 | finance.yahoo.comAbeona Therapeutics Shares Fall After Q2 MissAugust 13, 2026 | finance.yahoo.comAbeona Therapeutics: Earnings Sell-Off Could Be A Buy OpportunityAugust 13, 2026 | seekingalpha.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.27 at the beginning of 2026. Since then, ABEO stock has increased by 15.6% and is now trading at $6.09. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc. (NASDAQ:ABEO) released its quarterly earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.12. The biopharmaceutical company earned $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. Read the conference call transcript. When did Abeona Therapeutics' stock split? Abeona Therapeutics's stock reverse split on the morning of Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' top institutional investors include AWM Investment Company Inc. (2.61%), Montanova Capital LLC (0.87%), Bank of New York Mellon Corp (0.36%) and Headlands Technologies LLC (0.22%). Insiders that own company stock include Vishwas Seshadri, Joseph Walter Vazzano, Brendan M O'malley, Madhav Vasanthavada, Leila Alland, Faith L Charles, Christine Berni Silverstein, Michael Amoroso, Mark Alvino and Eric Crombez. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE). Company Calendar Last Earnings8/13/2026Today8/23/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 ABEO's financial health is in the Green zone, according to TradeSmith. ABEO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101Employees90Year Founded2013Price Target and Rating Average Price Target for Abeona Therapeutics$19.33 High Price Target$21.00 Low Price Target$17.00 Potential Upside/Downside+217.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$71.18 million Net MarginsN/A Pretax Margin-306.81% Return on Equity-41.69% Return on Assets-30.36% Debt Debt-to-Equity Ratio0.01 Current Ratio6.63 Quick Ratio6.40 Sales & Book Value Annual Sales$5.82 million Price / Sales59.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book2.72Miscellaneous Outstanding Shares57,180,000Free Float53,124,000Market Cap$348.23 million OptionableOptionable Beta1.35 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ABEO) was last updated on 8/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
